167 related articles for article (PubMed ID: 21502195)
1. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jul; 39(7):1149-54. PubMed ID: 21502195
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
[TBL] [Abstract][Full Text] [Related]
3. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.
Fu A; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Sep; 1352():208-13. PubMed ID: 20599807
[TBL] [Abstract][Full Text] [Related]
4. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
Sumbria RK; Boado RJ; Pardridge WM
Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
[TBL] [Abstract][Full Text] [Related]
5. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.
Boado RJ; Pardridge WM
Drug Metab Dispos; 2009 Dec; 37(12):2299-304. PubMed ID: 19741036
[TBL] [Abstract][Full Text] [Related]
6. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
8. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
[TBL] [Abstract][Full Text] [Related]
10. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
[TBL] [Abstract][Full Text] [Related]
11. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.
Pardridge WM; Boado RJ
Pharm Res; 2009 Oct; 26(10):2227-36. PubMed ID: 19609743
[TBL] [Abstract][Full Text] [Related]
13. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
[TBL] [Abstract][Full Text] [Related]
14. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
15. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
[TBL] [Abstract][Full Text] [Related]
16. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
17. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
18. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
Zhou QH; Fu A; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Mol Pharm; 2011 Feb; 8(1):280-5. PubMed ID: 21141969
[TBL] [Abstract][Full Text] [Related]
19. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]